PMID- 27498671
OWN - NLM
STAT- MEDLINE
DCOM- 20170613
LR  - 20220409
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 9
IP  - 11
DP  - 2016 Nov
TI  - The power of two: an update on fixed-dose combinations for type 2 diabetes.
PG  - 1453-1462
LID - 10.1080/17512433.2016.1221758 [doi]
AB  - Patients with type 2 diabetes mellitus (T2DM) are unlikely to maintain glycemic 
      control with monotherapy, and will eventually require therapy with multiple 
      antihyperglycemic agents (AHAs). Combination therapy regimens with multiple AHAs 
      may be complex and negatively impact patient adherence. Fixed-dose combinations 
      (FDCs) are used successfully for management of numerous chronic diseases. Areas 
      covered: This article includes a brief overview of the add-on approach of current 
      treatment guidelines for T2DM and reviews the evidence supporting the utility of 
      oral FDCs in the treatment of T2DM, including recently developed oral FDCs 
      (2010-2016). Benefits regarding safety and tolerability, adherence and cost are 
      also discussed. Finally, the barriers limiting the use of FDCs and how these 
      barriers may be overcome are addressed. Expert commentary: Therapeutic strategies 
      including FDCs need to be implemented on a larger scale. FDCs have the potential 
      to simplify treatment regimens, improve adherence and provide long-term glycemic 
      control.
FAU - Harris, Stewart B
AU  - Harris SB
AD  - a Department of Family Medicine, Centre for Studies in Family Medicine, Schulich 
      School of Medicine & Dentistry , Western University , London , Ontario , Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160912
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Combinations
MH  - Drug Costs
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects/economics
MH  - *Patient Compliance
MH  - Practice Guidelines as Topic
OTO - NOTNLM
OT  - Adherence
OT  - combination therapy
OT  - fixed-dose combination
OT  - type 2 diabetes mellitus
EDAT- 2016/08/09 06:00
MHDA- 2017/06/14 06:00
CRDT- 2016/08/09 06:00
PHST- 2016/08/09 06:00 [pubmed]
PHST- 2017/06/14 06:00 [medline]
PHST- 2016/08/09 06:00 [entrez]
AID - 10.1080/17512433.2016.1221758 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2016 Nov;9(11):1453-1462. doi: 
      10.1080/17512433.2016.1221758. Epub 2016 Sep 12.